Related Experiment Videos
Insights
Hepatitis B vaccination is safe and effective, particularly for newborns and children. This strategy helps prevent chronic Hepatitis B virus (HBV) infection and associated liver diseases like cancer.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) infection is a global health concern, with over 200 million chronic carriers worldwide.
- Chronic HBV infection significantly increases the risk of severe liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
- Prevalence varies geographically, with higher rates in Asia and Africa, often linked to perinatal and infant transmission, leading to chronic carriage.
Purpose of the Study:
- To report on the efficacy and safety of a developed Hepatitis B vaccine.
- To provide an overview of vaccination experiences, focusing on newborns and children.
- To inform recommended vaccination strategies, target populations, and optimal schedules based on clinical trial data.
Main Methods:
- Review of clinical trial data on Hepatitis B vaccine safety, immunogenicity, and efficacy.
- Analysis of vaccination outcomes in diverse populations, with a specific focus on neonatal and pediatric cohorts.
- Evaluation of transmission patterns and risk factors in different geographical regions.
Main Results:
- The Hepatitis B vaccine has demonstrated a strong safety profile.
- The vaccine is highly immunogenic, inducing protective antibody responses.
- Clinical trials confirm the vaccine's effectiveness in preventing Hepatitis B virus infection, especially when administered early.
Conclusions:
- Hepatitis B vaccination is a crucial public health intervention.
- Vaccination strategies, particularly for newborns and children, are effective in preventing chronic HBV infection and its long-term complications.
- The data supports the widespread implementation of Hepatitis B vaccination programs globally.
Abstract:
Hepatitis B virus (HBV) infections occur world-wide and more than 200 million people have been estimated to be chronic carriers of HB surface antigen (HBsAg). Long-term chronic carriage of HBsAg has been associated with an increased risk of chronic active hepatitis (CAH), cirrhosis and hepatocellular carcinoma (HCC). In Western countries, the prevalence of HBV infection is low in the general population. Only particular subgroups, for the most part adults, are at risk of such infections: health care workers, haemodialysis patients, transfusion patients, drug abusers and homosexuals. In Asia and tropical Africa, however, the prevalence of HBV infection is relatively high. Transmission occurs mainly during the perinatal period and infancy. Infection at a young age often results in the chronic carrier state. A hepatitis B vaccine has been developed in France and has been demonstrated to be safe, immunogenic, and effective in preventing HBV infection. Extensive experience from clinical trials now makes it possible to recommend vaccination strategies in terms of target populations and of optimal schedules. This paper reports the results of hepatitis B vaccination and, in particular, presents an overview of the vaccination experience in newborns and children.